Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Current address: Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec, Canada.
Curr Protoc. 2023 Apr;3(4):e744. doi: 10.1002/cpz1.744.
The recent development of human cerebral organoids provides an invaluable in vitro model of human brain development to assess the toxicity of natural or man-made toxic substances. By recapitulating key aspects of early human neurodevelopment, investigators can evaluate with this three-dimensional (3D) model the effect of certain compounds on the formation of neuronal networks and their electrophysiological properties with more physiological relevance than neurons grown in monolayers and in cultures composed of a unique cell type. This promising potential has contributed to the development of a large number of diverse protocols to generate human cerebral organoids, making interlaboratory comparisons of results difficult. Based on a previously published protocol to generate human cortical organoids (herein called cerebral organoids), we detail several approaches to evaluate the effect of chemicals on neurogenesis, apoptosis, and neuronal function when exogenously applied to cultured specimens. Here, we take as an example 4-aminopyridine, a potassium channel blocker that modulates the activity of neurons and neurogenesis, and describe a simple and cost-effective way to test the impact of this agent on cerebral organoids derived from human induced pluripotent stem cells. We also provide tested protocols to evaluate neurogenesis in cerebral organoids with ethynyl deoxyuridine labeling and neuronal activity with live calcium imaging and microelectrode arrays. Together, these protocols should facilitate the implementation of cerebral organoid technologies in laboratories wishing to evaluate the effects of specific compounds or conditions on the development and function of human neurons with only basic cell culture equipment. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Generation of human cerebral organoids from pluripotent stem cells Support Protocol 1: Human pluripotent stem cell culture Basic Protocol 2: Evaluation of neurogenesis in cerebral organoids with ethynyl deoxyuridine labeling Basic Protocol 3: Calcium imaging in cerebral organoids Basic Protocol 4: Electrophysiological evaluation of cerebral organoids with microelectrode arrays Support Protocol 2: Immunostaining of cerebral organoids.
人脑类器官的最新发展为评估天然或人为有毒物质的毒性提供了一种非常有价值的体外人脑发育模型。通过再现人类早期神经发育的关键方面,研究人员可以使用这种三维(3D)模型评估某些化合物对神经元网络形成及其电生理特性的影响,其具有比在单层和由独特细胞类型组成的培养物中生长的神经元更高的生理相关性。这种有前途的潜力促成了大量不同的生成人脑类器官的方案的发展,使得实验室之间的结果难以比较。基于之前发表的生成人类皮质类器官的方案(本文称为脑类器官),我们详细介绍了几种方法,用于评估外源应用于培养物标本时化学物质对神经发生、细胞凋亡和神经元功能的影响。在这里,我们以 4-氨基吡啶为例,这是一种钾通道阻断剂,可调节神经元的活性和神经发生,并描述了一种简单且具有成本效益的方法来测试该药物对源自人类诱导多能干细胞的脑类器官的影响。我们还提供了经过测试的方案,用于通过乙炔脱氧尿苷标记评估脑类器官中的神经发生,以及通过实时钙成像和微电极阵列评估神经元活性。总之,这些方案应该有助于希望使用基本细胞培养设备评估特定化合物或条件对人类神经元发育和功能影响的实验室实施脑类器官技术。 © 2023 作者。Wiley Periodicals LLC 出版的《当代协议》。基础方案 1:从多能干细胞生成人脑类器官 支持方案 1:人类多能干细胞培养 基础方案 2:通过乙炔脱氧尿苷标记评估脑类器官中的神经发生 基础方案 3:脑类器官中的钙成像 基础方案 4:使用微电极阵列评估脑类器官的电生理特性 支持方案 2:脑类器官的免疫染色。